First Dose Level found to be Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
“Investigators at Erasmus Medical Center (“Erasmus MC”) in the Netherlands have completed the safety evaluation of patients enrolled in the first dose level of the dose escalation design in the Phase 1b/2 study. The combination of Ampligen and Imfinzi was found to be generally well-tolerated with no SAE or DLT. Based on these positive results, escalation to the next dose will occur according to protocol design and AIM expects the next cohort of patients to begin dosing very soon. Subjects will be in treatment for up to 48 weeks, or until confirmed disease progression or another discontinuation criterion is met. They will be monitored for response according to RECIST 1.1.”
Share:
More News
“Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing
“Our encouraging Phase 2 data for GRANITE in MSS-CRC continue to mature and demonstrate durable benefit over time. With two additional months of follow-up, relative progression-free survival has further improved in the analysis of all patients treated with GRANITE, and most notably, in those with a lower tumor burden at
“Patients in the EU with ROS1 -positive non-small cell lung cancer and NTRK -positive solid tumors face a great unmet need for new therapies that may improve their outcomes and address or delay the difficult issue of treatment resistance,” said Joseph Fiore, vice president, global program lead, repotrectinib, Bristol Myers
“The acquisition of Biotheus builds on our successful ongoing collaboration on BNT327/PM8002 and other investigational bispecific antibodies,” said Prof. Ugur Sahin, M.D., Ph.D., CEO and co-founder of BioNTech. “We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional checkpoint inhibitors.
